Ceftolozane Tazobactam – Injection products
Exceptions or additions to the recognized standards
Minimum Inhibitory | Disk Diffusion | |||||
|---|---|---|---|---|---|---|
| Pathogen | S | I | R | S | I | R |
| Bacteroides fragilis | ≤8/4 | 16/4 | ≥32/4 | - | - | - |
S = Susceptible; I = Intermediate; R = Resistant
On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.